“…Although the IOP-29 was introduced relatively recently, in 2017 (Viglione et al, 2017), there are already numerous published research articles in the literature, including a quantitative literature review (Giromini & Viglione, 2022) and a bivariate diagnostic test accuracy meta-analysis (Puente-López et al, 2023). Of note, these research studies have been conducted in many different countries, including the United States (Holcomb et al, 2023), United Kingdom (Bosi et al, 2022; Winters et al, 2021), Australia (Gegner et al, 2022), Belgium (Blavier et al (2023), France (Banovic et al, 2022), Portugal (Giromini, Barbosa, et al, 2020), Italy (Giromini et al, 2018; Pignolo et al, 2023; Roma et al, 2020), Lithuania (Ilgunaite et al, 2022), Norway (Grønnerød et al, 2023), Slovenia (Šömen et al, 2021), Brazil (Carvalho et al, 2021), and the Netherlands (Boskovic et al, 2022), leading to very similar results in all these different cultural contexts. Perhaps more importantly, the quantitative literature review by Giromini and Viglione (2022) also demonstrated that the IOP-29 provides incremental validity when used in conjunction with established SVTs such as the MMPI or PAI validity scales or established PVTs such as the Test of Memory Malingering (Tombaugh, 1996), suggesting that it could be a useful addition to the toolbox of assessors conducting a multimethod assessment of symptom and/or performance validity.…”